

Radiotherapy alone in locally advanced cervical cancer: a palliative treatment? Real-world data

Radioterapia isolada no câncer cervical localmente avançado: um tratamento paliativo? Dados do mundo real

Tiago Pontes Braz¹, Eduardo Paulino¹, Alvaro Henrique Ingles Garces², Rachele Grazziotin Reisner³, Gustavo Guitmann⁴, Luiz Claudio Santos Thuler², Andreia Cristina de Melo²

ABSTRACT

Objective: To investigate the benefit of radiotherapy alone in patients diagnosed with locally advanced cervical cancer when the addition of chemotherapy was contraindicated. **Methods:** A single-center cohort study of patients diagnosed with locally advanced cervical cancer as defined by the FIGO 2009 (stage IB2 to IVA) and contraindication for concomitant chemotherapy was retrospectively evaluated. Patients included were treated with radiotherapy in a curative intent and those patients who completed the external beam radiotherapy were considered for brachytherapy. Patient's demographics, reasons for not receiving concomitant chemotherapy and treatment responses were analyzed. Disease-free survival (DFS) and overall survival (OS) were calculated. **Results:** With a median follow-up of 13.9 months (range 0.10-81.8), the median DFS was 11.6 months (95% CI: 10.2-13.1), and the median OS was 15.9 months (95% CI: 11.5-20.3). **Conclusion:** This real-world study provides descriptive information confirming that radiotherapy with curative intent should be offered to patients with locally advanced cervical cancer even when chemotherapy is not an option due to clinical or laboratory contraindications.

Keywords: Uterine cervical neoplasms; Radiotherapy; Brachytherapy; Antineoplastic agents.

1. Brazilian National Cancer Institute, Clinical Oncology Division, Rio de Janeiro - RJ, Brazil.
2. Brazilian National Cancer Institute, Clinical Research Division, Rio de Janeiro - RJ, Brazil
3. Brazilian National Cancer Institute, Radiotherapy Division, Rio de Janeiro - RJ, Brazil.
4. Brazilian National Cancer Institute, Surgical Oncology Division, Rio de Janeiro - RJ, Brazil.

Financial support: none to declare.

Conflicts of interest: The authors declare no conflict of interest relevant to this manuscript.

Correspondence author: Tiago Pontes Braz, Brazilian National Cancer Institute, Rio de Janeiro - RJ, Brazil., Clinical Oncology, Rio de Janeiro - RJ, Brazil.
E-mail: tiagopontesbraz@gmail.com / melo.andreia@uol.com.br

Received on: September 12, 2020 | Accepted on: April 16, 2021

DOI: <https://doi.org/10.5935/2526-8732.20210014>



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>).

RESUMO

Objetivo: Investigar o benefício da radioterapia isolada em pacientes com diagnóstico de câncer cervical localmente avançado quando a adição de quimioterapia foi contraindicada. **Métodos:** Um estudo de coorte unicêntrico de pacientes com diagnóstico de câncer cervical localmente avançado, conforme definido pela FIGO 2009 (estágio IB2 a IVA) e contraindicação para quimioterapia concomitante foi retrospectivamente avaliada. Os pacientes incluídos foram tratados com radioterapia com intenção curativa e os pacientes que completaram a radioterapia com feixe externo foram considerados para braquiterapia. Dados demográficos do paciente, razões para não receber quimioterapia concomitante e respostas ao tratamento foram analisados. Sobrevida livre de doença (SLD) e sobrevida global (SG) foram calculadas. **Resultados:** Com um acompanhamento médio de 13,9 meses (intervalo de 0,10-81,8), a SLD mediana foi de 11,6 meses (IC 95%: 10,2-13,1) e a SG mediana foi de 15,9 meses (IC 95%: 11,5-20,3). **Conclusão:** Este estudo do mundo real fornece informações descritivas que confirmam que a radioterapia com intenção curativa deve ser oferecida a pacientes com câncer cervical localmente avançado, mesmo quando a quimioterapia não é uma opção devido a contraindicações clínicas ou laboratoriais.

Descritores: Neoplasias do colo uterino; Radioterapia; Braquiterapia; Agentes antineoplásicos.

INTRODUCTION

Cervical cancer (CC) is a public health problem. It is the fourth most common cancer and the fourth leading cause of cancer death among females around the world,¹ with 410,000 deaths expected for 2030.² Approximately 85% of cases and deaths occur in low- and middle-income countries (LMIC).³⁻⁵ According to the Brazilian National Cancer Institute (INCA), 16,590 new cases are estimated for 2021 in Brazil, representing the third most commonly diagnosed cancer in women in this country.⁶ Human papillomavirus (HPV) infection is the most important risk factor and can be detected in 99.7% of cases.^{7,8}

In 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised the staging and treatment recommendations. Patients with locally advanced disease (stages IB3 to IVA) have worse prognosis, with increased risk of recurrence and shorter overall survival (OS) than patients diagnosed at earlier stages. Five-year OS for stages III and IV varies from 40% to 15%, respectively.⁹

The recommended treatment for locally advanced disease is external beam radiotherapy (EBRT) concomitant with weekly cisplatin followed by high dose (HDR) or low dose (LDR) brachytherapy. Since the early 2000s, increasing utilization of HDR has been adopted, in opposition to LDR.¹⁰ Five phase 3 studies,¹¹⁻¹⁵ including patients with FIGO 2009 stages IB2 to IVA, showed a 30 to 50% reduction in the risk of death in patients receiving chemoradiation. The improved efficacy of the combined modality is due to the direct cytotoxicity effect of the platin compound, its radiosensitization action in tumor cells, and the control of subclinical metastases.¹⁶ However, the benefit of concurrent chemotherapy with radiotherapy in patients with FIGO stage IIIB disease

was not substantially proven until 2018, when a randomized phase 3 trial demonstrated a significant improvement of disease-free survival (DFS) and OS in favor of the combination therapy with an absolute benefit of 8.5% and 8%, respectively.¹⁷

Moreover, it is important to note that all trials comparing the benefits of the association of chemotherapy and radiotherapy included patients suitable for the combination approach, excluding patients considered not fit for chemoradiotherapy. Cisplatin, the drug of choice for concurrent therapy, is well known to be nephrotoxic, and patients with moderate to severe renal insufficiency are not eligible to receive this medication. Moreover, patients with compromised performance status; comorbidities such as severe heart or liver disease, neuropathy, and hearing deficiency are ineligible for this combined treatment.

Although the benefits of combined chemotherapy and radiation therapy in CC treatment have been evident since 1999, when papers showing survival gains were published, the radiotherapy and brachytherapy techniques used at that time were the standard treatment. Currently, the population chosen for combined treatment is always the one with the best clinical and prognostic conditions. Thus, radiotherapy alone and brachytherapy are reserved for those with the worst clinical condition and poor prognostic factors.

The objective of this study was to evaluate the results of radiotherapy alone in patients diagnosed with locally advanced CC when the addition of chemotherapy was contraindicated such as those with renal insufficiency, performance status >2, severe baseline neuropathy, advanced comorbidities, and advanced age. This group considered of inferior prognosis was evaluated

exploring the clinical outcomes proportioned by this single-modality therapy.

METHODS

The current study was approved by the Ethics in Human Research Committee of INCA (CEP-INCA), Rio de Janeiro, Brazil, under the number CAAE 48092415.3.0000.5274 and conducted in accordance with the good clinical practice guidelines.

This was a retrospective single-center cohort study of consecutive patients with locally advanced CC, as defined by the FIGO 2009 (stages IB2 to IVA) and contraindication for concomitant chemotherapy and treated between January 2010 and December 2012. Patients were submitted to physical examination and imaging according to the physicians' discretion. Data collected included patients' demographics, the reason for contraindication to concomitant chemotherapy, clinical and response data and dates of the last follow-up or death. All data was anonymized after collection and before the analysis.

Patients included in this study were treated with radiotherapy in a curative manner and were not eligible for concomitant approach due to, among many reasons, cisplatin contraindication, including renal insufficiency defined as creatinine clearance lower than 50mL/min (as per institutional guidelines), performance status >2, hearing loss grade ≥2, and severe baseline neuropathy. Patients with metastatic CC (FIGO stage IVB), except those with affected paraaortic lymph nodes, other histology than squamous cell carcinoma or adenocarcinoma were not included.

Patients who completed the EBRT were considered for brachytherapy. The median value of total dose of radiotherapy (EBRT + brachytherapy) was assumed as cutoff point. Adverse events (AEs) were graded according to the common terminology criteria for adverse events (CTCAE v.4.03). The responses were discriminated clinically and using imaging tests when considered indicated. Clinical benefit (CB) was defined as best response of complete response (CR), partial response (PR) or stable disease (SD) by RECIST 1.1, when a radiological assessment was undertaken, as well as a clinical response through physical examination and categorized according to the WHO criteria as follows: complete response with complete resolution of tumor as judged clinically, partial clinical response with more than 50% regression of initial tumor volume, and no responders were patients with a minimal response (less than 50% regression of the initial tumor volume), no change or local/distant progression.

Disease-free survival (DFS) was defined from the date of radiotherapy onset until the date of tumor recurrence or death by any cause and was censored at the date of the last follow-up. OS was calculated from the date of first treatment to the date of death and was censored at the date of the last follow-up. Survival rates were calculated by Kaplan-Meier curves and were compared by the log-rank test. A

Cox regression analysis was fitted to analyze the association between clinical characteristics and OS. With the purpose of adjusting for confounding factors variables with $p < 0.15$ in the univariate analysis were included in a forward stepwise manner in the multivariate model. In all analysis a p -value lower than 0.05 was considered statistically significant. For the statistical analysis, Statistical Package for Social Sciences (SPSS) software, version 24, was used.

RESULTS

From January 2010 to December 2012, 2,224 were diagnosed with locally advanced CC at Brazilian National Cancer Institute, whereas 182 patients from this cohort were diagnosed with locally advanced CC at INCA and were treated with radiotherapy alone due to contraindication to the concomitant chemotherapy and enrolled in this study. Baseline characteristics are presented in Table 1. The median age at the time of initial diagnosis was 60 years (range 26.4-101.4), and the most frequent histology was squamous cell carcinoma (88.5%). The majority of patients were white (52.7%), with performance status 1 (58.6%) at diagnosis, and 109 patients (59.9%) were diagnosed as FIGO stage III.

Table 1. Clinical and pathological characteristics of patients

| Characteristics | N (%) |
|--------------------------------------|-------------------|
| Median age (range) | 60 (26.4 - 101.4) |
| Ethnicity* | |
| White | 96 (52.7) |
| Non-white | 86 (47.3) |
| Histological subtype | |
| Squamous cell carcinoma | 161 (88.5) |
| Adenocarcinoma | 20 (11.0) |
| Other | 1 (0.5) |
| FIGO stage | |
| IB2 | 13 (7.1) |
| II | 49 (26.9) |
| III | 109 (59.9) |
| IVA | 11 (6.0) |
| Performance status | |
| 1 | 106 (58.3) |
| 2 | 56 (30.8) |
| 3 | 19 (10.4) |
| Unknown | 1 (0.5) |
| Creatinine clearance (mL/min) | |
| < 50 | 120 (65.9) |
| ≥ 50 | 62 (34.1) |
| Smoking | |
| Yes | 76 (42) |
| No | 106 (58) |
| Total | 182 (100) |

FIGO: International Federation of Gynecology and Obstetrics
*Self-reported

Contraindications for concomitant treatment with cisplatin use according to physicians' discretion were renal dysfunction in 65.9% (n=120), impaired performance status in 26.9% (n=49), and other reasons in 29.1% of the cases (n=53); some patients had more than one contraindication for cisplatin use.

Regarding radiotherapy, 153 patients (84.1%) received 25 to 30 fractions of EBRT, and 29 (15.9%) patients received less than 25 fractions due to treatment-related AEs, clinical deterioration or progression of disease during radiotherapy. A total of 105 patients (59%) received ≥ 5000 cGy, and 94 patients did not receive brachytherapy. A complete description of treatment with EBRT and brachytherapy is shown in Table 2.

Table 2. Distribution of radiotherapy and brachytherapy

| Radiotherapy/Brachytherapy | N (%) |
|----------------------------|------------|
| Radiotherapy (cGy) | |
| < 700 | 2 (1.1) |
| 700-1800 | 10 (5.6) |
| 2000-3000 | 7 (3.9) |
| 4000-4600 | 52 (29.2) |
| 5000-5400 | 105 (59.0) |
| Missing | 6 |
| Brachytherapy (cGy) | |
| 1400-1800 | 4 (4.7) |
| 2000-3000 | 82 (95.3) |
| Missing | 2 |
| No brachytherapy | 94 |
| Total dose (cGy)* | |
| 1st Quartile | 6900 |
| Median | 7400 |
| 3rd Quartile | 7440 |

Differences in total are due to missing data; percentages were calculated considering only patients with available data.
*Refers to 86 cases

The most common AEs reported were actinic colitis (14.9%), pelvic pain (11.6%), and bladder-vaginal fistula (7.2%). Other less frequent toxicities were constipation (3.9%), actinic cystitis (3.8%), rectovaginal fistula (3.8%), urinary incontinence (3.3%), and nausea (3.3%).

Response assessment was documented in 162 patients (89%), and 116 patients had clinical benefit (CR - 71 patients, PR - 43 patients, and SD - 2 patients) – Table 3. Of note, response assessment was done using gynecological physical examination in 82.6% of patients and only 17.4% had a radiological evaluation.

With a median follow-up of 13.9 months (range: 0.10-81.8), the median DFS was 11.6 months (95% CI: 10.2-13.1), and the median OS was 15.9 months (95% CI: 11.5-20.3) (Figure 1). Table 4 summarizes the differences in DFS and OS between the subgroups.

Table 3. Response to radiotherapy

| Response | N (%) |
|---------------------------------|------------|
| CR | 71 (43.8) |
| PR | 43 (26.5) |
| PD | 46 (28.4) |
| SD | 2 (1.2) |
| Clinical benefit (CR + PR + SD) | 116 (71.6) |
| Missing | 20 |

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease




Figure 1. Kaplan-Meier estimates

There was a statistical difference in terms of DFS in the following subgroups: age ≥ 65 years ($p=0.031$), performance status ($p= 0.037$), and brachytherapy ($p<0.001$). Concerning OS a significant difference was observed in the following subgroups: age ($p=0.017$), smoking ($p=0.029$), and brachytherapy ($p<0.001$).

After controlling for potential confounding factors, the multivariable Cox proportional hazards model showed that only age ≥ 65 years was associated with the risk of recurrence or distant metastasis (Table 5). Similarly, age ≥ 65 years and performance status = 3 were independently associated with the risk of death (Table 6).

DISCUSSION

In this retrospective study, locally advanced CC patients not eligible for combined treatment due to

their clinical or laboratory conditions were treated exclusively with radiotherapy. The main objective was to evaluate the outcomes of radiotherapy alone in this real-world practice population.

It is undeniable to mention that the dose and correct technique of radiotherapy are determinants for the success of local control and pelvic relapse¹⁸ and the effect of curative radiotherapy for CC may be improved by the inclusion of brachytherapy.¹⁴ The objective of irradiation is to achieve maximum tumor control with the lowest incidence of sequelae and with an acceptable

Table 4. Disease-Free Survival and overall survival according to the subgroups.

| | DFS (months) Median (95% CI) | OS (months) Median (95% CI) |
|--|-------------------------------------|------------------------------------|
| Age ≥ 65 years | | |
| Yes | 17.2 (9.8-24.6) | 20.3 (15.7-25.0) |
| No | 10.3 (9.2-11.5) | 12.2 (8.8-15.7) |
| p-value | 0.031 | 0.017 |
| Histological subtype | | |
| Squamous cell carcinoma | 11.5 (10.4-12.6) | 15.5 (11.0-20.1) |
| Adenocarcinoma | 17.2 (3.2-31.2) | 19.8 (10.6-29.1) |
| p-value | 0.574 | 0.312 |
| FIGO stages | | |
| I/II | 20.1 (6.2-34.2) | 20.3 (13.1-27.6) |
| III/IV | 11.2 (9.8-12.5) | 15.2 (10.5-20.0) |
| p-value | 0.457 | 0.493 |
| Performance status | | |
| 1 | 12.1 (8.1-16.2) | 17.2 (11.5-22.9) |
| 2 | 10.8 (7.9-13.8) | 17.8 (10.5-25.1) |
| 3 | 9.7 (2.0-17.3) | 11.8 (4.0-19.6) |
| p-value | 0.037 | 0.058 |
| Creatinine clearance (mL/min) | | |
| < 50 | 11.1 (9.5-12.7) | 15.5 (10.0-21.1) |
| ≥ 50 | 12.0 (6.4-17.6) | 17.2 (10.0-24.5) |
| p-value | 0.794 | 0.666 |
| Smoking | | |
| Yes | 9.7 (7.3-12.2) | 12.6 (8.3-16.8) |
| No | 12.6 (8.5 -16.6) | 19.5 (13.8- 24.9) |
| p-value | 0.064 | 0.029 |
| Radiotherapy (cGy) | | |
| < 5000 | 12.0 (5.1-18.8) | 15.5 (7.4-23.7) |
| ≥ 5000 | 11.6 (10.4-12.8) | 17.2 (12.3-22.1) |
| p-value | 0.786 | 0.994 |
| Brachytherapy | | |
| No | 6.2 (3.6-8.8) | 8.1 (5.6-10.5) |
| Yes | 20.5 (6.5-34.4) | 33.0 (17.8-48.2) |
| p-value | < 0.001 | < 0.001 |
| Total dose of radiotherapy (cGy)* | | |
| < 7400 | 19.8 (17.4-22.2) | 26.9 (7.1-46.8) |
| ≥ 7400 | 33.0 (18.7-47.4) | 37.9 (24.2-51.6) |
| p-value | 0.625 | 0.583 |
| Overall | 11.6 (10.2-13.1) | 15.9 (11.5-20.3) |

DFS: Disease free survival; OS: Overall survival

Bold text indicates a statistically significant difference with a p-value < 0.05

Table 5. Risk of recurrence or distant metastasis

| | HR (95%CI) | p-value | aHR* (95%CI) | p-value |
|--|----------------|--------------|----------------|--------------|
| Age | | | | |
| < 65 years | Ref | | Ref | |
| ≥ 65 years | 0.7 (0.5-0.95) | 0.025 | 0.7 (0.5-0.95) | 0.025 |
| Histological subtype | | | | |
| Adenocarcinoma | | | | |
| Squamous cell carcinoma | 1.2 (0.7-2.0) | 0.571 | | |
| FIGO stages | | | | |
| I/II | Ref | | | |
| III/IV | 1.3 (0.7-2.6) | 0.412 | | |
| Performance status | | | | |
| 1 | Ref | | | |
| 2 | 1.2 (0.8-1.7) | 0.452 | | |
| 3 | 1.9 (1.1-3.1) | 0.018 | | |
| Creatinine clearance (mL/min) | | | | |
| < 50 | Ref | | | |
| ≥ 50 | 0.9 (0.7-1.3) | 0.728 | | |
| Smoking | | | | |
| No | Ref | | | |
| Yes | 1.3 (1.0-1.9) | 0.082 | | |
| Total dose of radiotherapy (cGy)* | | | | |
| ≥ 7400 | Ref | | | |
| < 7400 | | 0.626 | | |

Bold text indicates a statistically significant difference with a p-value < 0.05 Ref = Reference

* Only age was retained by the adjusted model.

Table 6. Risk of death

| | HR (95%CI) | p-value | aHR (95%CI) | p-value |
|--|----------------|--------------|----------------------|--------------|
| Age | | | | |
| < 65 years | Ref | | Ref | |
| ≥ 65 years | 0.7 (0.5-0.97) | 0.031 | 0.6 (0.5-0.9) | 0.014 |
| Histological subtype | | | | |
| Adenocarcinoma | Ref | | Ref | |
| Squamous cell carcinoma | 1.3 (0.8-2.3) | 0.324 | | |
| FIGO stages | | | | |
| I/II | Ref | | Ref | |
| III/IV | 1.3 (0.7-2.6) | 0.449 | | |
| Performance status | | | | |
| 1 | Ref | | Ref | |
| 2 | 1.3 (0.9-1.8) | 0.251 | | |
| 3 | 1.8 (1.1-3.0) | 0.027 | 1.9 (1.1-3.2) | 0.015 |
| Creatinine clearance (mL/min) | | | | |
| < 50 | Ref | | Ref | |
| ≥ 50 | 0.9 (0.6-1.3) | 0.571 | | |
| Smoking | | | | |
| No | Ref | | Ref | |
| Yes | 1.5 (1.1-2.1) | 0.025 | | |
| Total dose of radiotherapy (cGy)* | | | | |
| ≥ 7400 | Ref | | Ref | |
| < 7400 | 0.9 (0.5-1.5) | 0.584 | | |

Bold text indicates a statistically significant difference with a p-value < 0.05 Ref = Reference

quality of life. Tumor control is related to its extension and the dose of radiation given.¹⁷ Whereas doses of 4500-5000cGy are adequate to control subclinical disease, doses in the range of 8500 to 9000cGy are required to eradicate larger tumors.¹⁸ In the current study, only 45% of patients received more than 70Gy, mainly because there was a shortage of patients treated with brachytherapy. With a relatively short follow-up (13.9 months), the death rate was as high as 70.9% caused primarily by cancer, with only 24.7% of patients still alive. These findings contrast negatively when compared with other randomized trials and meta-analyses.¹¹⁻¹⁵ Such disproportionate mortality could be justified by underestimated staging.

However, in this study, 15.9% patients (29 cases) received less than 25 radiotherapy fractions, 51.6% patients (94 cases) did not receive brachytherapy. Such disparities can be attributed to reduced performance status and clinical deterioration during radiotherapy and delayed onset of brachytherapy. Moreover, social development in the city of Rio de Janeiro and peripheral cities is mostly precarious. Transportation problems to get to the hospital associated with poor food and housing conditions can contribute to the clinical worsening. During data collection, hospitalizations for clinical complications such as kidney failure and infectious conditions that evolved to severe sepsis and death were mentioned. Finally, the wait to perform brachytherapy is long and serves patients from institutions outside the Brazilian National Cancer Institute.

Cisplatin is nephrotoxic chemotherapy and has many contraindications. Because of that, several studies have emerged evaluating other drugs to be combined with radiotherapy for treatment of locally advanced CC. Therefore, when any contraindication to cisplatin is identified, other options could be considered, allowing patients to have treatment with the same extension of benefit when compared to the ones treated with concomitant cisplatin. Carboplatin is an effective radiosensitizer as seen in a prospective study that compared carboplatin 100mg/m² with cisplatin combined to radiotherapy. It was found a similar overall response rate and no difference in survival outcomes at three years.¹⁹ The use of carboplatin, therefore, is supported by small phase 1 and 2 studies, and there is preclinical evidence of synergism of this drug with radiotherapy.²⁰⁻²⁴ Ana Morais et al. carried out a retrospective study comparing radiotherapy plus cisplatin 40 mg/m² and radiotherapy plus carboplatin AUC2 in locally advanced CC stage IIB-IVA. That analysis did not find any difference in terms of side effects comparing cisplatin and carboplatin in combination with radiotherapy, response, PFS and OS.²⁵ Gemcitabine is another possibility to be considered for chemoradiotherapy. In a Mexican trial, gemcitabine was used with radiotherapy for patients with obstructive nephropathy and kidney dysfunction.²⁶ Nine patients were treated and completed the chemoradiotherapy regimen, 89% achieved CR, and one patient had persistent disease. At a median follow-up of 11

months, all patients were alive and two had evidence of recurrent disease. Paclitaxel and 5-fluorouracil were also trialed, with no consistent benefit observed.^{27,28} Finally, combined radiotherapy and hyperthermia can be considered as another valid option for the first-line treatment of advanced-stage CC with benefits in terms of local control rate, improved survival, limited restrictions on its clinical application and low costs.²⁹

In this study, smoking was a prominent factor since the median overall survival was 12.6 months for smokers versus 19.5 months for non-smokers. The mutagenic effect of cigarette smoking occurs in cervical cells and this leads to progression from squamous intraepithelial lesion to cervical cancer. Finally, smoking increases the frequency of chromosomal damage.³⁰

The majority of patients in this analysis were stage III (59.9%). FIGO stage III CC patients have been a point of disagreement in many clinical trials. Because of this lack of more definitive information, a randomized phase 3 trial was developed to analyze stage III CC patients at the Tata Memorial Hospital, Mumbai, India. Between July 2003 and September 2011, 850 women were enrolled. With a median follow-up of 88 months, the 5-year DFS was 52.3% (95% CI: 52.2%-52.4%) in the chemoradiotherapy arm and 43.8% (95% CI: 43.7%-43.9%) in the radiotherapy arm, with an unadjusted hazard ratio (HR) for relapse or death of 0.81 (95% CI: 0.68-0.98; $p=0.03$). At 5 years, the OS was 54% (95% CI: 53.9%-54.1%) in the chemoradiotherapy arm and 46% (95% CI: 45.9%-46.1%) in the radiotherapy arm, with an unadjusted HR for death of 0.82 (95% CI: 0.68-0.98; $p=0.03$). Finally, it was showed that chemoradiotherapy using weekly cisplatin is significantly better in terms of DFS and OS compared with radiotherapy alone in women with stage IIIB squamous cell carcinoma.¹⁷

Therefore, chemoradiotherapy remains the preferred therapy for patients with locally advanced CC, with good performance status, adequate renal function, and no other debilitating comorbidities. In the current study, patients not eligible for concomitant approach achieved some clinical benefit (tumor control) with exclusive radiotherapy, showing that even when contraindication to chemotherapy exists, the dose/schedule of EBRT should be maintained at a curative approach.

The results of this study confirm once again the importance of HPV vaccination and screening for prevention and early diagnosis of CC. Moreover, the continuous investigation for alternative approaches to cisplatin, such as the use of immunotherapy or PARP inhibitors concomitant to radiotherapy should be pursued.

Real-world studies could be useful as a measure in understanding health care data collected under real-life practice circumstances,³¹ and the results can help to define if a treatment is effective and safe also in a real-world setting and not only within a clinical trial.

As a real-world study, there are several limitations to this report, as there is a possible bias due to its retrospective nature. However, the aim to

characterize the benefits of EBRT in real-world practice, as the population studied is, in general, excluded from the clinical trials, was achieved.

Differences in characteristics among patients enrolled in clinical trials and those in real-world setting could highlight the limitations of generalizing clinical trial data.³²

The key strength of the current study is the large number of patients identified using a single-institution register, where patients could have received a more homogeneous evaluation during the whole process, including documentation.

CONCLUSION

Our real-world data demonstrated that, despite the lower survival outcomes rates, radiotherapy alone with curative intent should be offered to patients with locally advanced cervical cancer not suitable for chemotherapy. However, for those with good performance status but kidney dysfunction, chemotherapy regimens with gemcitabine or carboplatin should be considered. Finally, the current study provides descriptive information confirming that radiotherapy with curative intent should be offered to patients with locally advanced CC even when chemotherapy is not an option due to clinical/laboratorial contraindications.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394-424.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*. 2006 May;24(14):2137-50.
3. Villa LL. Cervical cancer in Latin America and the Caribbean: the problem and the way to solutions. *Cancer Epidemiol Biomarkers Prev*. 2012 Sep;21(9):1409-13.
4. LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery. *Gynecol Oncol Rep*. 2017 Nov;22:16-20.
5. De Vuyst H, Alemany L, Lacey C, Chibwesa CJ, Sahasrabudhe V, Banura C, et al. The burden of human papillomavirus infections and related diseases in Sub-Saharan Africa. *Vaccine*. 2013 Dec;31(5):F32-46.
6. Ministério da Saúde (BR). Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA). Estimativa 2020 – Incidência de Câncer no Brasil [Internet]. Brasília (DF): Ministério da Saúde/INCA; 2020; . Available from: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf>
7. Colpani V, Bidinotto AB, Falavigna M, Giozza SP, Benzaken AS, Pimenta C, et al. Prevalence of papillomavirus in Brazil: a systematic review protocol. *BMJ Open*. 2016 Nov;6(11):e011884.
8. Ayres ARG, Silva GA. Prevalência de infecção do colo do útero pelo HPV no Brasil: revisão sistemática. *Rev Saúde Pública*. 2010 Oct;44(5):963-74.
9. Ries LAG, Young Junior JL, Keel GE, Eisner MP, Lin YD, Horner MJ. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics. Bethesda: National Cancer Institute (NCI)/SEER Program; 2007.
10. Banerjee R, Kamrava M. Brachytherapy in the treatment of cervical cancer: a review. *Int J Womens Health*. 2014 May;6:555-64.
11. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*. 1999 Apr;340(15):1144-53.
12. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med*. 1999 Apr;340(15):1154-61.
13. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol*. 2000 Apr;18(8):1606-13.
14. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Junior WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. *J Clin Oncol*. 1999 May;17(5):1339-48.
15. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med*. 1999 Apr;340(15):1137-43.
16. Thomas G, Dembo A, Fyles A, Gadalla T, Beale F, Bean H, et al. Concurrent chemoradiation in advanced cervical cancer. *Gynecol Oncol*. 1990 Sep;38(3):446-51.
17. Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. *JAMA Oncol*. 2018 Apr;4(4):506-13.

18. Perez CA, Breaux S, Madoc-Jones H, Bedwinek JM, Camel HM, Purdy JA, et al. Radiation therapy alone in the treatment of carcinoma of uterine cervix. I. Analysis of tumor recurrence. *Cancer*. 1983 Apr;51(8):1393-402.
19. Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. *Oncologist*. 2013 Jul;18(7):843-9.
20. Corn BW, Hernandez E, Anderson L, Fein DA, Dunton CJ, Heller P. Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report. *Am J Clin Oncol*. 1996 Jun;19(3):317-21.
21. Dubay RA, Rose PG, O'Malley DM, Shalodi AD, Ludin A, Selim MA. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. *Gynecol Oncol*. 2004 Jul;94(1):121-4.
22. Duenas-Gonzalez A, Cetina L, Sánchez B, Gomez E, Rivera L, Hinojosa J, et al. A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. *Int J Radiat Oncol Biol Phys*. 2003 Aug;56(5):1361-5.
23. Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. *Gynecol Oncol*. 2003 Jun;89(3):499-503.
24. Micheletti E, La Face B, Bianchi E, Cagna E, Apostoli P, Ruggeri G, et al. Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study. *Am J Clin Oncol*. 1997 Dec;20(6):613-20.
25. Sebastião AM, Rocha LSS, Gimenez RD, Barros LAB, Fukushima JT, Silva SCS, et al. Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?. *Eur J Obstet Gynecol Reprod Biol*. 2016 Jun;201:161-5.
26. Cetina L, Rivera L, Candelaria M, Garza J, Dueñas-González A. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. *Anticancer Drugs*. 2004 Sep;15(8):761-6.
27. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. *J Clin Oncol*. 1996 Mar;14(3):792-5.
28. Thomas G, Dembo A, Ackerman I, Franssen E, Balogh J, Fyles A, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. *Gynecol Oncol*. 1998 May;69(2):137-45.
29. Franckena M. Review of radiotherapy and hyperthermia in primary cervical cancer. *Int J Hyperth*. 2012;28(6):543-8.
30. Cerqueira EM, Santoro CL, Donozo NF, Freitas BA, Pereira CA, Bevilacqua RG, et al. Genetic damage in exfoliated cells of the uterine cervix. Association and interaction between cigarette smoking and progression to malignant transformation? *Acta Cytol*. 1998 May/Jun;42(3):639-49.
31. Mahajan R. Real world data: additional source for making clinical decisions. *Int J Appl Basic Med Res*. 2015 Aug;5(2):82.
32. Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. *J Oncol Pract*. 2015 Nov;11(6):491-7.